Previous 10 | Next 10 |
Mechelen, Belgium; 15 November 2021; 1 6 . 45 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca ® (filgotinib 200mg tablets) for the treatme...
Galapagos (GLPG +5.2%) ADRs are trading higher after two Wall Street predicted a key catalyst for the company when AbbVie (NYSE:ABBV) releases cystic fibrosis data early next year. Arguing that Galapagos (NASDAQ:GLPG) can earn compelling royalties from AbbVie (ABBV), RBC Capital Markets highl...
Galapagos NV (GLPG) Q3 2021 Earnings Conference Call November 5, 2021 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director, Investor Relations Onno van de Stolpe - Chief Executive Officer Bart Filius - Chief Operating Officer Walid Abi-Saab - Chief Medical Officer Michele Manto ...
Image source: The Motley Fool. Galapagos NV (NASDAQ: GLPG) Q3 2021 Earnings Call Nov 5, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Galapagos NV (GLPG) Q3 2021 Earnings Call Transcript
Galapagos (NASDAQ:GLPG): Q3 GAAP EPS of -€ 1.83. Revenue of € 317.9M (-1.2% Y/Y) Press Release For further details see: Galapagos reports Q3 results
First nine months 202 1 financial results : Group revenues of € 317.9 million Operating loss of € 175.7 million Net loss of € 119.6 million Cash and c urrent financial in...
After the recent FDA black box warning of JAKi, Arena Pharmaceuticals' share price has rallied recovering some of its 2021 losses. In this article, Etrasimod's ulcerative colitis phase 2 data will be analyzed and explain what our views for the S1P-R class moving forward. Arena Pha...
C ontinuing filgotinib 200mg among induction non-respon d ers at w eek 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE) T reatment with fil...
1 , 374 patients enrolled into the phase 3 study across 369 global sites Topline data anticipated in H 1 202 3 Galapagos will assume responsibility f or the D IVERSITY study Mechelen, B...
Mechelen, Belgium ; 17 September 2021 ; 13.15 CET ; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...